These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Long-term tolerance of oral gold therapy in rheumatoid arthritis. Frequency and intensity of undesirable side effects]. Goebel KM; Storck U Schweiz Med Wochenschr; 1985 Dec; 115(49):1775-7. PubMed ID: 3937234 [TBL] [Abstract][Full Text] [Related]
9. Injectable gold dermatitis and proteinuria: retreatment with auranofin. Tosi S; Cagnoli M; Guidi G; Murelli M; Messina K; Colombo B Int J Clin Pharmacol Res; 1985; 5(4):265-8. PubMed ID: 2932399 [TBL] [Abstract][Full Text] [Related]
10. [Comparative evaluation of the effectiveness of gold preparations and D-penicillamine and their tolerance in rheumatoid arthritis. I. The effect on the indicators of their activity and tolerance]. Slobodina GA; Kanevskaia MZ; Krel' AA; Chichasova NV Revmatologiia (Mosk); 1989; (1):8-16. PubMed ID: 2501852 [TBL] [Abstract][Full Text] [Related]
11. Erythrocyte membrane gold levels after treatment with auranofin and sodium aurothiomalate. Iqbal MS; Saeed M; Taqi SG Biol Trace Elem Res; 2008; 126(1-3):56-64. PubMed ID: 18649049 [TBL] [Abstract][Full Text] [Related]
12. An analysis of worldwide safety experience with auranofin. Heuer MA; Pietrusko RG; Morris RW; Scheffler BJ J Rheumatol; 1985 Aug; 12(4):695-9. PubMed ID: 3932651 [TBL] [Abstract][Full Text] [Related]
13. [Indications and contraindications for systemic gold therapy]. Schattenkirchner M Wien Klin Wochenschr Suppl; 1984; 156():3-7. PubMed ID: 6442054 [TBL] [Abstract][Full Text] [Related]